About the Event

The MTPConnect WA Life Sciences Innovation Hub invites you to join the monthly WA MTP Sector Spotlight Series event.

Our monthly breakfast series is an opportunity for representatives from across the MTP sector to connect, collaborate and learn about upcoming opportunities, and hear the stories and successes of WA organisations developing health and medical innovations. Join us over a light breakfast in the last week of each month at the Harry Perkins Institute of Medical Research.

Join Brandon Capital’s Dr Mikkelsen in conversation with MTPConnect’s Dr Tracey Wilkinson for a fireside chat discussing funding and investment opportunities available to WA start-ups and SMEs through the Brandon BioCatalyst.

Featuring Brandon Capital – insights into investing in life science.

Brandon Capital is a leading life science venture capital firm, with a strong global presence supported by key partnerships and team members across the US and UK. From early-stage seed investment through to expansion capital, Brandon Capital supports life science companies from proof-of-concept through to commercialisation. In Australia and New Zealand, the company delivers Brandon BioCatalyst (formerly the Medical Research Commercialisation Fund), a unique collaboration of Australian superannuation funds, CSL, the Australian and New Zealand governments, Australian state governments and more than 50 leading medical research institutes and research hospitals. Brandon BioCatalyst supports the development and commercialisation of early-stage biomedical discoveries originating from Australian and New Zealand member research organisations, providing both capital and expertise to guide the successful development of new therapies. This unique collaboration is in serve of a single purpose: progressing the next generation of medical therapies and technology which improve health and save lives.

About our speaker

Dr Helga Mikkelsen Dr Mikkelson is an Investment Analyst at Brandon Capital, which manages the BioCatalyst (formerly the Medical Research Commercialisation Fund). Following degrees in Chemical Engineering and Biotechnology, Helga completed her PhD in microbiology at the University of Cambridge and postdoctoral research in bacterial genetics at Imperial College London. She subsequently managed the development of anti-infective medical devices in urology at CamStent Ltd (Cambridge, UK). Since her move to Australia in 2016, Dr Mikkelson has worked with the Telethon Kids Institute to commercialise inhaled drug treatments for respiratory disease and is a co-founder of Respirion Pharmaceuticals, which develops a new treatment for chronic lung infections in patients with cystic fibrosis.

Agenda

• 7:30am Informal networking (COVID restrictions permitting) at Coffee Anatomy, ground floor of the Perkins Institute
• 8:00am Guided fireside chat
• 9:00am Event close

Information:

For any queries, please get in touch with Rebekah Craggs at rebekah.craggs@mtpconnect.org.au

Click here for more information and to REGISTER.

---